“Preclinical data suggest that telaglenastat and palbociclib have synergistic activity in KRAS-mutated tumors, and may offer a new approach to the challenges associated with treating KRAS-mutated cancers,” said
Telaglenastat is designed to block glutamine consumption in tumor cells. Genetic alterations, such as mutations in KRAS, can cause cancer cells to increase metabolism of glutamine. In preclinical studies with KRAS-mutated cancer models, telaglenastat showed synergistic antitumor effects when used in combination with CDK4/6 inhibitors, such as palbociclib, enhancing cell cycle arrest and blocking cancer cell proliferation. The Phase 1/2 clinical trial (NCT03965845) will evaluate the safety and anti-tumor activity of the telaglenastat plus palbociclib combination in patients with locally advanced/metastatic KRAS-mutated CRC and KRAS-mutated NSCLC that are refractory or intolerant to standard therapies.
This is the second trial initiated by Calithera as part of an ongoing clinical trial agreement with Pfizer. The first trial, which is investigating the combination of telaglenastat with the PARP inhibitor talazaporib in patients with renal cell carcinoma (RCC), triple negative breast cancer (TNBC) and CRC began enrolling patients in
About Telaglenastat
Telaglenastat is an investigational selective oral inhibitor against human glutaminase, a critical enzyme that enables cancer cells to utilize glutamine for metabolism and survival.Tumors commonly exhibit metabolic alterations that increase their dependence on glutamine. In pre-clinical studies, telaglenastat has demonstrated synergistic antitumor activity when used in combination with standard-of-care therapies. Telaglenastat in combination with everolimus met the primary endpoint of improving PFS compared to everolimus with placebo in ENTRATA, a randomized Phase 2 clinical study. The compound is currently being evaluated in multiple ongoing combination trials, including with cabozantinib in the global, pivotal Phase 2 CANTATA study.
About Calithera
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the success of Calithera’s collaborations with Pfizer, the potential for telaglenastat to be developed in combination with therapeutics, such as palbociclib or talazoparib, to improve patient outcomes, safety, tolerability and efficacy of telaglenastat, the overall advancement of telaglenastat in clinical trials, the unmet need in the treatment of patients with advanced disease, Calithera’s plans to continue development of telaglenastat in combination with PARP inhibitor talazoparib for the treatment of TNBC, RCC and CRC as well as the related timing for clinical trials, and Calithera’s plans to continue development of the combination of telaglenastat plus palbociclib in CRC and NSCLC patients. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Annual Report on Form 10-K filed with the
SOURCE:
INVESTOR CONTACT:
ir@Calithera.com
650-870-1071
MEDIA CONTACT:
hannahhurdle@sambrown.com
805-338-4752
Source: Calithera Biosciences, Inc.